- recruitingPHASE3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
This study compares a new combination treatment for advanced melanoma (lifileucel plus pembrolizumab) against pembrolizumab alone. It's for people who haven't had treatment for their advanced melanoma before. The aim is to see if the new combination is more effective and safe.
United States · Australia · Belgium - recruiting
Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults
This study looks at why some young people get melanoma, a type of skin cancer. Researchers are checking environment, lifestyle, and genes to find out what increases the risk. The goal is to better understand melanoma and help prevent it in children, teenagers, and young adults.
Germany · Italy · Poland - ongoing, recruitingPhase I and Phase II (Integrated)- Other
CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
This study is looking at a new way to give nivolumab, a cancer medicine, through an injection under the skin. It's for people with various advanced cancers like lung, kidney, and liver cancer, to see how the body handles the medicine and if it's safe.
Spain · Netherlands · Italy - recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
This study looks at how new cancer treatments affect daily life for people with long-term cancer. It aims to understand how to best support them while they are on these treatments, often for many months or years.
Canada - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This study is testing a drug called entrectinib for different cancers in adults and children. It focuses on cancers with a specific change in their cells, called ROS1 gene fusion, to see if entrectinib can be a new treatment option.
United Kingdom - recruitingPHASE4
Dabrafenib and/or Trametinib Rollover Study
This study allows patients already on dabrafenib and/or trametinib for certain cancers to continue treatment if their doctor thinks it's helping and they meet specific criteria. It's for people already in another study.
United States · Argentina · Austria - active not recruitingPHASE1
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study is testing a new cell therapy for certain cancers that have a specific protein. It aims to see if it's safe and how well people tolerate it. The therapy uses your own modified cells to fight the cancer. Some participants will also receive a small amount of radiation.
United States · Canada - recruiting
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
This study, called 'NIP IT!', aims to find tiny traces of cancer in patients who have finished their main treatment. We hope to use new technology and AI to spot cancer coming back very early, even before scans can see it. The goal is to help more people stay cancer-free for longer.
Canada - active not recruitingPHASE3
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
This study looks at two drugs, encorafenib and binimetinib, for people with a specific type of high-risk skin cancer called melanoma, after surgery. It aims to see if these drugs can stop the cancer from coming back, compared to standard check-ups.
Argentina · Australia · Austria - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France - active not recruitingPHASE2
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study looks at a new combination of drugs, fianlimab and cemiplimab, for melanoma skin cancer. We want to see if this combination works better and is safe compared to cemiplimab alone for people with certain stages of melanoma that can be removed by surgery.
United States · Australia · Austria - active not recruiting
A Study of Tumor Imaging With Multispectral Optoacoustic Tomography
This study looks at a new imaging method, called Multispectral Optoacoustic Tomography (MSOT), for breast cancer and melanoma. We want to see how well MSOT images breasts right before a biopsy, to help doctors get a clearer picture of suspicious areas.
United States · Germany - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This study is for adults with specific cancers that have a change called BRAF V600. It's testing if two drugs, vemurafenib and cobimetinib, already used for a type of skin cancer, can help treat these other cancers. The goal is to find new treatments for patients.
United Kingdom - recruitingPHASE1, PHASE2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
This study is testing a new drug, BMS-986340, by itself and with other treatments for different advanced cancers. Researchers want to find the safest dose and see how well it works. This is the first time BMS-986340 has been tried in people.
United States · Australia · Canada - recruiting
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
The SHERLOCK study aims to find tiny bits of cancer DNA in your blood after treatment. This helps doctors spot if cancer might return early, hoping to improve long-term health. We're looking for new ways to track different types of cancer.
Canada - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - recruitingNA
Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
This study is looking at how a natural substance called Urolithin A might help the immune system of people with certain cancers who are having a type of treatment called immune checkpoint inhibitors. Some get Urolithin A, others get a dummy pill.
Germany - active not recruitingPHASE1
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
This study compares a new medicine called GME751 to an existing treatment, Keytruda, for people with melanoma that has been removed by surgery. It checks if GME751 works similarly and is safe.
United States · Bosnia and Herzegovina · Brazil - recruitingPHASE2
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
This study looks at combining two treatments — immunotherapy and a special type of radiotherapy called carbon ion therapy — for certain cancers that haven't worsened with current immunotherapy. It aims to see if this combination is safe and effective.
Germany · Italy - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY
This study looks at a new way to treat high-risk skin cancer (melanoma) using a drug called Keytruda before surgery. Researchers want to see how well Keytruda shrinks the cancer and if it's safe for patients.
France - active not recruitingPHASE3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This study is testing a new medicine, pembrolizumab, for people in the UK with a type of skin cancer called melanoma that has been removed by surgery but is considered high-risk. It aims to see if the medicine can stop the cancer from coming back.
United States · Australia · Belgium - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - active not recruitingPHASE3
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade (PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)
This study looks at a new way to treat melanoma, a type of skin cancer, using existing drugs. It combines an older chemotherapy drug (dacarbazine) with newer immunotherapy treatments (pembrolizumab, nivolumab, ipilimumab) for people whose cancer hasn't responded to immunotherapy alone. We want to see if this combination helps more people.
Germany - active not recruitingPHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
This study is looking at a new combination of medicines, relatlimab and nivolumab, for advanced melanoma. It aims to see if this combination works better than nivolumab alone for melanoma that has spread or can't be removed by surgery.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This study is testing a new drug, NUC-7738, for people with advanced cancers like solid tumours and lymphoma. It aims to see how safe the drug is, how it works in the body, and if it helps treat these cancers, sometimes combined with pembrolizumab.
United Kingdom - active not recruitingPHASE1, PHASE2
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
This study is testing a new drug, BI-1607, combined with two existing cancer drugs, pembrolizumab and ipilimumab, for advanced melanoma. Researchers want to see if this new combination is safe, effective, and helps patients whose cancer hasn't responded to other treatments.
Germany · Spain · United Kingdom - recruiting
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
This study aims to understand why advanced melanoma treatments stop working for some patients. We're looking at samples from tumours and blood to find clues that predict when treatments might become less effective, helping us improve future care.
United Kingdom - recruitingPHASE3
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
This study looks at treating brain tumours from melanoma or lung cancer. It compares standard treatments (like immunotherapy) plus focused radiation to standard treatments alone, aiming to find the best way to improve lives and reduce side effects.
Italy · Netherlands · Spain - active not recruitingPHASE3
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
This study is looking at whether a drug called nivolumab can help prevent melanoma skin cancer from coming back in people who have had surgery to remove it. It compares nivolumab to a dummy treatment (placebo) in adults and children at high risk of their cancer returning.
United States · Australia · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
France - active not recruitingPHASE2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
This study uses a special scan called a PET/CT with a medicine called zirconium Zr 89 crefmirlimab berdoxam. It’s for people with advanced melanoma, Merkel cell cancer, kidney cancer, or lung cancer. We want to see if this scan can help predict how well immunotherapy will work for their cancer.
United States · Australia · Belgium - active not recruitingPHASE2
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
This study looks at new treatments (Ceralasertib alone or with Durvalumab) for people with advanced melanoma that has stopped responding to standard immunotherapy. It aims to see how well they work and if they are safe.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This study is testing different combinations of new drugs, including EOS-448, with or without standard treatments for advanced cancers like lung and head & neck cancer, and melanoma. Researchers want to see if these combinations are safe and effective.
United States · Belgium · France - authorisedTherapeutic exploratory (Phase II)
Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613
This study is looking at how well two medicines, fianlimab and cemiplimab, work together to treat a type of skin cancer called melanoma. Researchers are checking how long people live after having this combination treatment and if the cancer comes back or gets worse.
Ireland - active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitors
This study, called PICASSO, is looking at a new treatment called MaaT013 for advanced melanoma. It aims to see how safe MaaT013 is when given alongside standard cancer drugs and if it can help patients live longer and respond better to treatment.
France - active not recruitingPHASE2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
This study is looking for new ways to treat advanced melanoma, a type of skin cancer. It's testing combinations of new medicines (LXH254, LTT462) with existing ones (Trametinib, Ribociclib) in people whose melanoma has progressed after previous treatments. The goal is to see how well these new combinations work and if they are safe.
United States · Argentina · Australia - active not recruitingNA
VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer
This study looks into a new, keyhole surgery method (videoendoscopic radical inguinal lymphadenectomy) for penile cancer that might lead to fewer problems after the operation. It's comparing it with the traditional open surgery to see if the keyhole method is a good option for future use.
United Kingdom - recruiting
Ex VIvo DEtermiNed Cancer Therapy
This study, called EVIDENT, wants to see if we can test a tiny piece of your tumour in the lab to predict how well cancer treatments will work for you. It's for people with various solid cancers, like bladder or kidney cancer, who are having surgery or a biopsy.
United Kingdom - active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
United States · Denmark · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This study looks at a new combination treatment (Vibostolimab with Pembrolizumab) for melanoma skin cancer that has a high chance of coming back. It compares this combination to an existing treatment (Pembrolizumab alone) to see if it can stop the cancer from returning.
Austria · France · Spain - recruitingNA
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This study looks at adding special radiation to standard care for rare cancers that have spread a little. It wants to see if this addition helps people live longer compared to standard care alone.
Belgium · France · Germany - not yet recruiting
LATe TreatmENT Related Toxicity in Melanoma (LATENT)
This study looks at the long-term side effects of immunotherapy for advanced melanoma. Researchers will review existing medical records of patients who responded well to treatment for at least three years, aiming to improve future patient care and support.
United Kingdom - recruitingPHASE1, PHASE2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
This study is testing a new drug, BI-1808, by itself and with another medicine, pembrolizumab (Keytruda®), for people with advanced cancers. The goal is to see how safe the new drug is, what side effects it causes, and find the right dose for future studies.
United States · Denmark · Hungary - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
This study is looking at a new medicine, GME751, which is very similar to an existing cancer drug called Keytruda (pembrolizumab). It's for people with certain stages of skin cancer (melanoma) who need treatment after their initial cancer care. We want to see how GME751 works in the body compared to Keytruda.
Romania · Germany · Italy - active not recruitingPHASE1
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
This study looks at a new drug, MB097, combined with another treatment, Pembrolizumab, for people with melanoma that hasn't responded to previous therapy. Researchers want to see if this combination is safe and how well people tolerate it.
France · Italy · Spain - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
This study is looking at a new way to give medicine for advanced melanoma. We want to see if an injection under the skin works as well as the usual drip into a vein. This might make treatment easier for patients.
United States · Australia · Austria